keyword
https://read.qxmd.com/read/37577792/recent-advances-in-the-management-of-postmenopausal-women-with-non-atypical-endometrial-hyperplasia
#21
REVIEW
H Ren, Y Zhang, H Duan
Non-atypical endometrial hyperplasia is a benign disease without significant somatic genetic changes. Postmenopausal women with non-atypical endometrial hyperplasia have a significant risk of progression to endometrial cancer and persistent endometrial hyperplasia. Most cases of atypical endometrial hyperplasia in postmenopausal women are treated surgically, including hysterectomy. At present, the treatment of postmenopausal women with non-atypical endometrial hyperplasia is still controversial. Correct and timely diagnosis and treatment are of great significance to prevent progression of the lesion...
October 2023: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/37540307/effects-of-hysteroscopic-surgery-combined-with-progesterone-therapy-on-fertility-and-prognosis-in-patients-with-early-endometrial-cancer-and-atypical-endometrial-hyperplasia-or-endometrial-intraepithelial-neoplasia-a-meta-analysis
#22
JOURNAL ARTICLE
Xiabin Ye, Tonghuai Li
OBJECTIVE: This meta-analysis aimed to evaluate the effects of hysteroscopic surgery combined with progesterone therapy on fertility and prognosis in patients with early endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN). METHODS: Studies on hysteroscopic surgery combined with progesterone therapy for patients with early-stage EC, AEH, or EIN were searched from Embase, Web of Science, PubMed, and Cochrane Library databases...
January 2024: Archives of Gynecology and Obstetrics
https://read.qxmd.com/read/37511804/critical-overview-of-serous-endometrial-intraepithelial-cancer-treatment-systematic-review-of-adjuvant-options
#23
REVIEW
Carlo Ronsini, Antonella Reino, Rossella Molitierno, Maria Giovanna Vastarella, Elvira La Mantia, Pasquale De Franciscis
SEIC is a non-invasive lesion of the endometrial epithelium considered to be the precursor to uterine serous carcinoma (USC) and is just as aggressive as USC. Currently, there are no reliable data about the behavior and prognosis of SEIC; therefore, the therapeutic management approach is not clear. Method : A systematic search of the Pubmed, Scopus and Embase databases was conducted, following the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results : Of the 296 studies that matched the search criteria, only 9 met the inclusion criteria, covering a total of 81 patients...
June 22, 2023: Life
https://read.qxmd.com/read/37406458/her2-erbb2-immunohistochemical-expression-and-copy-number-status-in-ovarian-mucinous-tumors
#24
JOURNAL ARTICLE
Marie C Smithgall, Anna Yemelyanova, Susan Mathew, Swarna Gogineni, Bing He, Taotao Zhang, Brian D Robinson, Jiangling J Tu
Primary mucinous ovarian carcinoma (MOC) is a rare ovarian epithelial cancer, which is often refractory to chemotherapy. HER2-targeting therapy is being increasingly considered in gynecologic malignancies. Although there have been limited studies examining the HER2 status of such tumors, the criteria for HER2 expression scoring have not been standardized for MOC as it has for other sites. This study aimed to survey immunohistochemical HER2 expression patterns in MOC and its precursor, mucinous borderline tumor in correlation with fluorescence in situ hybridization (FISH)...
June 30, 2023: International Journal of Gynecological Pathology
https://read.qxmd.com/read/37386498/risk-reducing-salpingo-oophorectomy-among-chinese-women-at-increased-risk-of-breast-and-ovarian-cancer
#25
JOURNAL ARTICLE
Zheng Feng, Ke Zuo, Xingzhu Ju, Xiaojun Chen, Wentao Yang, Hao Wen, Lin Yu, Xiaohua Wu
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for women at increased risk of breast and ovarian cancer. We launched a prospective study of women receiving RRSO, including those with mutations in genes beyond BRCA1/2. PATIENTS AND METHODS: 80 women were enrolled for RRSO with sectioning and extensively examining the fimbriae (SEE-FIM) protocol between October 2016 and June 2022. The majority of participants had inherited susceptibility gene mutations or a family history suggesting ovarian cancer risk, while patients with isolated metastatic high-grade serous cancer of unknown origin were also included...
June 29, 2023: Journal of Ovarian Research
https://read.qxmd.com/read/37329873/endometrial-cancer-patients-understanding-and-interest-in-weight-loss-surgery
#26
JOURNAL ARTICLE
R L Wiley, Diana L Urbauer, E Nugent, J Gallegos, L Ramondetta
OBJECTIVE: Obesity is a risk factor for endometrial hyperplasia (EH), endometrial intraepithelial neoplasia (EIN), and early type 1 endometrial cancer (EC) in 70%-90% of patients and is often a significant contributor to overall morbidity and mortality due to comorbidities. In 2011, bariatric surgery (BS) with lifestyle modification was identified as an intervention for reduction in overall mortality as well as risk for gynecologic cancers (Tsui et al., 2021). Our aim was to assess awareness of obesity as a risk factor and understanding of BS in an underinsured obese patient population with EC or EH...
June 15, 2023: Gynecologic Oncology
https://read.qxmd.com/read/37290247/association-of-body-mass-index-with-early-age-at-diagnosis-of-endometrial-intraepithelial-neoplasia
#27
JOURNAL ARTICLE
Kaitlin Nicholson, Annliz Macharia, Rachel Furuya, Chelsea Manning, Michele R Hacker, Devon A Harris, Katharine Esselen, Joseph Dottino
OBJECTIVE: Elevated body mass index (BMI) is a risk factor for endometrioid endometrial cancer and its precursor, endometrial intraepithelial neoplasia (EIN). Our objective was to describe the association between BMI and age at EIN diagnosis. METHODS: We conducted a retrospective study of patients diagnosed with EIN from 2010 to 2020 at a large academic medical center. Patient characteristics were stratified by menopausal status and compared using a chi-square or t-test...
June 6, 2023: Gynecologic Oncology
https://read.qxmd.com/read/37275440/rates-of-unanticipated-premalignant-and-malignant-lesions-at-the-time-of-hysterectomy-performed-for-pelvic-organ-prolapse-in-an-underscreened-population
#28
JOURNAL ARTICLE
Syem Barakzai, Emma Koltun-Baker, Samuel J F Melville, Enanyeli Rangel, Molly Dahl, Christina E Dancz
BACKGROUND: The rate of unanticipated premalignant or malignant pathology at the time of hysterectomy performed for pelvic organ prolapse has been previously reported to be 0.2%. It is not known whether this rate is similar in patients with limited access to regular medical care. OBJECTIVE: This study aimed to describe the rates of unanticipated premalignancy and malignancy at the time of hysterectomy performed for pelvic organ prolapse in an underscreened population and to determine the risk factors for unanticipated pathology...
May 2023: AJOG global reports
https://read.qxmd.com/read/37275288/serous-endometrial-intraepithelial-carcinoma-a-case-report
#29
Younesse Najioui, Nassia Karich, Anas Haloui, Achraf Miry, Amal Bennani
Serous endometrial intraepithelial carcinoma (SEIC) is a rare but highly aggressive form of uterine endometrial cancer. We report two cases of post-menopausal, 58-year-old patients with abundant vaginal bleeding and pelvic pain. The first patient had a history of surgical hysteroscopy in 2019 for an endocervical polyp. The second patient had a history of breast resection, axillary lymph node dissection, chemotherapy, radiation therapy, and tamoxifen therapy for breast carcinoma 6 years ago. An abdominal hysterectomy was performed in both patients...
2023: Pan African Medical Journal
https://read.qxmd.com/read/37142090/success-rates-of-sentinel-lymph-node-mapping-for-endometrial-cancer-in-patients-with-body-mass-index-45-compared-with-body-mass-index-%C3%A2-45
#30
JOURNAL ARTICLE
Nicole J Fennimore, Katherine Fitch, Jaime Kiff, Christine G Nguyen, Bharti Garg, Elizabeth G Munro, Amanda S Bruegl
STUDY OBJECTIVE: The objective is to evaluate the rate of sentinel lymph node (SLN) mapping in patients with body mass index (BMI [kg/m2 ]) BMI ≥ 45 compared with < 45. DESIGN: A retrospective chart review. SETTING: Three urban referral-based settings-1 academic and 2 community based. PATIENTS: Patients age ≥ 18 years, with endometrial intraepithelial neoplasia or clinical stage 1 endometrial cancer who underwent robot-assisted total laparoscopic hysterectomy with attempted SLN mapping between January 2015 and December 2021...
May 2, 2023: Journal of Minimally Invasive Gynecology
https://read.qxmd.com/read/37101898/educational-case-serous-endometrial-intraepithelial-carcinoma-and-endometrial-cancer
#31
Carl T McGary, Rodney Boyum
No abstract text is available yet for this article.
2023: Academic Pathology
https://read.qxmd.com/read/37046784/fertility-sparing-treatment-and-assisted-reproductive-technology-in-patients-with-endometrial-carcinoma-and-endometrial-hyperplasia-pregnancy-outcomes-after-embryo-transfer
#32
JOURNAL ARTICLE
Hilary Friedlander, Jennifer K Blakemore, David H McCulloh, M Elizabeth Fino
The goal of fertility-sparing treatment (FST) for patients desiring future fertility with EMCA, and its precursor EH, is to clear the affected tissue and revert to normal endometrial function. Approximately 15% of patients treated with FST will have a live birth without the need for assisted reproductive technology (ART). Despite this low number, little information exists on the pregnancy outcomes of patients who utilize ART. The purpose of this study was to evaluate pregnancy outcomes following embryo transfer in patients with EMCA or EH who elected for FST...
April 2, 2023: Cancers
https://read.qxmd.com/read/37035887/serum-expression-of-tumor-marker-ca242-in-patients-with-different-gynecological-diseases
#33
JOURNAL ARTICLE
Zhu Jing, L Huidan
OBJECTIVE: The aim of this study was to investigate the serum levels of CA242 in different types of gynecological diseases and its clinical significance. METHODS: A total of 1021 patients with gynecological diseases and 499 healthy female controls were included in the study. The serum CA242 levels were detected and median value, -log10  P value, and positive rate were calculated. Serum CA125 and HE4 levels of patients with ovarian lesions were measured, and the predictive value for ovarian cancer was statistically analyzed...
April 10, 2023: Laboratory Medicine
https://read.qxmd.com/read/37023446/systemic-progestins-and-progestin-releasing-intrauterine-device-therapy-for-premenopausal-patients-with-endometrial-intraepithelial-neoplasia
#34
JOURNAL ARTICLE
Yukio Suzuki, Ling Chen, June Y Hou, Caryn M St Clair, Fady Khoury-Collado, Alexandre Buckley de Meritens, Koji Matsuo, Alexander Melamed, Dawn L Hershman, Jason D Wright
OBJECTIVE: To estimate trends in use and outcomes of progestin therapy for premenopausal patients with endometrial intraepithelial neoplasia. METHODS: The MarketScan Database was used to identify patients aged 18-50 years with endometrial intraepithelial neoplasia from 2008 to 2020. Primary treatment was classified as hysterectomy or progestin-based therapy. Within the progestin group, treatment was classified as systemic therapy or progestin-releasing intrauterine device (IUD)...
May 1, 2023: Obstetrics and Gynecology
https://read.qxmd.com/read/37001577/association-between-intrauterine-device-use-and-endometrial-cervical-and-ovarian-cancer-an-expert-review
#35
REVIEW
Nicole Minalt, Amy Caldwell, Grace M Yedlicka, Sophia Joseph, Sharon E Robertson, Lisa M Landrum, Jeffrey F Peipert
The intrauterine device is one of the most effective forms of contraception. Use of the intrauterine device has increased in the United States over the last 2 decades. Two formulations are commercially available in the United States: the levonorgestrel-releasing intrauterine device and the copper intrauterine device. The levonorgestrel intrauterine device releases progestin, causing endometrial suppression and cervical mucus thickening, whereas the primary mechanism of action of the copper intrauterine device is to create a local inflammatory response to prevent fertilization...
August 2023: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/36944434/the-potential-role-of-glp-1-receptor-agonist-targeting-in-fertility-sparing-treatment-in-obese-patients-with-endometrial-malignant-pathology-a-call-for-research
#36
JOURNAL ARTICLE
Caroline J Violette, Ravi Agarwal, Rachel S Mandelbaum, José L González, Kurt M Hong, Lynda D Roman, Maximilan Klar, Jason D Wright, Richard J Paulson, Andreas Obermair, Koji Matsuo
INTRODUCTION: Most patients diagnosed with endometrial hyperplasia or cancer are obese. Obesity, along with polycystic ovarian syndrome (PCOS) and type-2 diabetes mellitus (T2DM), may act synergistically to increase risk of malignant endometrial pathology. Incidence of malignant endometrial pathology is increasing, particularly in reproductive aged women. In patients who desire future fertility, the levonorgestrel intrauterine device (LNG-IUD) is often utilized. If the first-line progestin therapy fails, there is not an effective second-line adjunct option...
April 2023: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/36929578/effects-of-a-fertility-sparing-re-treatment-for-recurrent-atypical-endometrial-hyperplasia-and-endometrial-cancer-a-systematic-literature-review
#37
REVIEW
Isao Murakami, Hiroko Machida, Tohru Morisada, Yasuhisa Terao, Tsutomu Tabata, Mikio Mikami, Yasuyuki Hirashima, Yoichi Kobayashi, Tsukasa Baba, Satoru Nagase
To examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment. A comprehensive systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Endometrial Cancer Committee. Multiple search engines, including PubMed/MEDLINE and the Cochrane Database, were searched in December 2021 using the keywords "Endometrial neoplasms," "Endometrial hyperplasia," "Endometrial intraepithelial neoplasia," "Fertility preservation," "Progestins," AND "Recurrence...
March 6, 2023: Journal of Gynecologic Oncology
https://read.qxmd.com/read/36908008/the-expression-of-stanniocalcin-1-estrogen-receptor-and-progesterone-receptor-in-endometrioid-endometrial-cancer
#38
JOURNAL ARTICLE
Gamze Erkılınç, Ramazan Oğuz Yüceer, Evrim Erdemoğlu, Zümrüt Arda Kaymak, Şerife Mehtap Darbaş, Kemal Kürşat Bozkurt, İbrahim Metin Çiriş
OBJECTIVE: To evaluate the expression of stanniocalcin-1 (STC-1) and to investigate the correlation of STC-1 with expression of estrogen receptor (ER), progesterone receptor (PR) and clinical parameters, histopathological findings and prognostic factors in endometrioid endometrial cancer (EEC). MATERIALS AND METHODS: In this retrospective study, STC-1 (cytoplasmic), ER (nuclear), and PR (nuclear) stainings were applied to tissue microarray sections of 89 EEC, 27 endometrial intraepithelial neoplasia (EIN), and 21 normal endometrium (NE)...
March 10, 2023: Turkish Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/36897162/endometrial-cancer-surgery-with-or-without-concomitant-stress-urinary-incontinence-surgery
#39
MULTICENTER STUDY
Katina Robison, Kyle Wohlrab, Chanelle J Howe, Holly E Richter, Vivian Sung, Kerri S Bevis, Christine Luis, Carolyn McCourt, Jerry Lowder, John Occhino, Gretchen Glaser, Elizabeth Lokich, Gena Dunivan, Amy Brown, Elena Tunitsky-Bitton, Stephanie Wethington, Chi Chiung Grace Chen, David Rahn, Matthew Carlson, Robin Cram, Christina Raker, Melissa A Clark
OBJECTIVE: To compare quality of life (QOL) among patients with endometrial intraepithelial neoplasia or early-stage endometrial cancer and stress urinary incontinence (SUI) who chose to have concomitant surgery with cancer surgery alone. METHODS: A multicenter, prospective cohort study was conducted across eight U.S. sites. Potentially eligible patients were screened for SUI symptoms. Those who screened positive were offered referral to urogynecology and incontinence treatment, including concomitant surgery...
April 1, 2023: Obstetrics and Gynecology
https://read.qxmd.com/read/36821789/comorbidity-of-urogynecological-and-gastrointestinal-disorders-in-female-patients-with-lichen-sclerosus
#40
JOURNAL ARTICLE
Jenni M Söderlund, Niina K Hieta, Samu H Kurki, Katri J Orte, Päivi Polo-Kantola, Sakari H Hietanen, Marjut Am Haataja
OBJECTIVE: Lichen sclerosus (LS) is a chronic inflammatory disease with a significant impact on quality of life. The aim of this cross-sectional case-control study was to characterize concomitant urogynecological and gastrointestinal disorders in female patients with LS. METHODS: A medical records search between 2004 and 2012 yielded 455 women and girls (mean age 64 years) with LS. The study cohort was compared with a 10-fold age- and sex-matched control cohort...
February 23, 2023: Journal of Lower Genital Tract Disease
keyword
keyword
17230
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.